FDAnews Drug Daily Bulletin

Sanofi, Ipsen and Eisai all took pipeline hits last week, with late-stage setbacks including Sanofi’s withdrawal of marketing applications for a blood-clot drug, Ipsen’s clinical hold for an investigational hemophilia drug and Eisai’s failed breast cancer trial. Sanofi withdrew all global applications for blood-clot drug semuloparin following comments from regulatory authorities, company spokeswoman Lauren Rose said.
Washington Drug Letter